^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BI-1

i
Other names: BI-1
Associations
Trials
Company:
Boehringer Ingelheim, Novartis
Drug class:
Apoptosis inhibitor
Associations
Trials
2years
Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction. (PubMed, Front Immunol)
Importantly, for therapeutic antibodies, the isotype backbone can have a strong impact on antibody function...Similarly, in AML patient samples, anti-VISTA-antibody on IgG4-Pro backbone, but not on IgG1-KO backbone, increased interactions, as a novel readout of activity, between immune cells and CD34+ AML cancer cells. In conclusion, the immune stimulatory effects of antagonistic anti-VISTA antibodies are defined by the antibody isotype and interaction with different Fc-gamma-receptors, highlighting the importance of understanding these interactions when designing immune stimulatory antibody therapeutics for immuno-oncology applications.
Journal • IO biomarker
|
CD34 (CD34 molecule) • VSIR (V-Set Immunoregulatory Receptor)
|
BI-1